Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics


Emergent Biosolutions, Inc. (EBS)

Today's Latest Price: $51.22 USD

6.12 (-10.67%)

Updated Mar 27 6:40pm

Add EBS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

EBS Stock Summary

  • With a one year PEG ratio of 199.86, Emergent BioSolutions Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 86.08% of US stocks.
  • EBS's current price/earnings ratio is 53.35, which is higher than 91.41% of US stocks with positive earnings.
  • Revenue growth over the past 12 months for Emergent BioSolutions Inc comes in at 41.36%, a number that bests 87.2% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Emergent BioSolutions Inc, a group of peers worth examining would be ON, CSGS, CIEN, AVAV, and AEIS.
  • Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.
EBS Daily Price Range
EBS 52-Week Price Range

EBS Stock Price Chart More Charts


EBS Price/Volume Stats

Current price $51.22 52-week high $71.19
Prev. close $57.34 52-week low $39.11
Day low $51.00 Volume 488,500
Day high $56.94 Avg. volume 453,258
50-day MA $58.22 Dividend yield N/A
200-day MA $52.34 Market Cap 2.66B

Emergent Biosolutions, Inc. (EBS) Company Bio


Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.

EBS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$51.22$47.14-8%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Emergent BioSolutions Inc. To summarize, we found that Emergent BioSolutions Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Emergent BioSolutions Inc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 5.79 years, is 0.21% -- higher than 67.86% of stocks in our DCF forecasting set.
  • Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 17 -- greater than 65.52% of US stocks with positive free cash flow.
  • Relative to other stocks in its sector (Healthcare), Emergent BioSolutions Inc has a reliance on debt greater than 60.26% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-10%
1%-9%
2%-8%
3%-7%
4%-6%
5%-5%

Want more companies with a valuation profile/forecast similar to that of Emergent BioSolutions Inc? See VIVO, ADMT, NUVA, PBH, and MD.


EBS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

EBS Latest Social Stream


Loading social stream, please wait...

View Full EBS Social Stream

EBS Price Returns

1-mo -12.71%
3-mo -5.06%
6-mo -2.99%
1-year 1.39%
3-year 76.38%
5-year 73.86%
YTD -5.06%
2019 -8.99%
2018 27.57%
2017 41.50%
2016 -17.92%
2015 46.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8173 seconds.